1. Core Product Specifications

Product Name: Tirzepatide
Chinese Name: Tirzepatide
CAS No.: 2023788-19-2
Peptide Type: Synthetic dual-target metabolic receptor agonist peptide, GLP-1R/GIPR dual agonist, hypoglycemic & weight-loss polypeptide, pharmaceutical API intermediate, preclinical research biochemical reagent
Molecular Formula: C???H???N??O??
Molecular Weight: 4813.4 Da
Appearance: White to off-white lyophilized crystalline powder, uniform loose texture, non-caking, odorless with ultra-low impurities
Purity: ≥98.0% (HPLC, research grade / pharmaceutical intermediate grade)
Form: Standard long-acting lipidated modified polypeptide, commercial stable specification
Moisture Content: ≤8.0%
Acetate Content: ≤12.0%
Peptide Content: ≥80.0%
Heavy Metals: ≤10ppm
Endotoxin: ≤50EU/mg
Solubility: Freely soluble in sterile water, normal saline and PBS buffer (pH 7.2), forming clear, stable and precipitate-free solutions
Transport Condition: Sealed, dry and light-proof transportation at room temperature
Storage Condition: Long-term dry powder storage at -20℃ in sealed, dry and dark environment; strictly avoid high temperature, strong light and moisture. Dissolved solutions must be aliquoted and frozen. Strictly avoid repeated freeze-thaw cycles to prevent attenuation of target bioactivity
Production Technology: Standard solid-phase peptide synthesis (SPPS), full-length precise sequence assembly, fatty acid side-chain lipidation modification, multi-stage high-precision HPLC purification, low-temperature vacuum freeze-drying activity locking technology
Core Bioactivity: Dual GLP-1/GIP receptor activation, glycolipid metabolism regulation, insulin sensitivity improvement, appetite suppression, fat loss and weight reduction, blood glucose stabilization, metabolic syndrome intervention
Shelf Life: 24 months for sealed dry powder stored at -20℃ under standard conditions
Usage Restriction: For scientific research, metabolic pharmacological experiments and preclinical new drug development only. Strictly prohibited for human clinical treatment, oral/injection administration and illegal applications